Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients
- 31 December 1991
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 15 (9) , 773-780
- https://doi.org/10.1016/0145-2126(91)90460-b
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemiaBritish Journal of Haematology, 1990
- Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitroBlood, 1990
- Expression of the multidrug resistance gene in myeloid leukemiasLeukemia Research, 1989
- Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup studyBritish Journal of Haematology, 1989
- Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot studyBlood, 1989
- High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.Journal of Clinical Oncology, 1987
- Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurementsBritish Journal of Haematology, 1986
- Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapyEuropean Journal of Cancer and Clinical Oncology, 1985
- Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells.Journal of Clinical Investigation, 1982
- Effect of interferon on colony formation in culture by blast cell progenitors in acute myeloblastic leukemiaBlood, 1980